Clinical Trial Search

Primary: 2 Year Disease-free Survival . — 9 percentage of participants

Primary: Cholesterol 24S-Hydroxylase (CH24H) Brain Enzyme Occupancy as a Function of TAK-935 Plasma Concentration at 45 Minutes Post-TAK-935 Dose — NA; 98; NA percentage of…

Primary: Modfied Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (mADCS-CGIC) — 1; 0; 5; 2 participants — p=0.98

Primary: Resistance Mechanism — 23; 1; 3; 4 participants

Primary: Mean Change From Baseline in the Aberrant Behavior Checklist Japanese Version (ABC-J) Irritability Subscale Score — -11.4; -7.5 units on a scale

Primary: Percentage of Participants Experiencing Adverse Events (AEs) — 100.0 Percentage of participants

Primary: PET/MRI Brain Activation — 0.21 percentage BOLD signal change

Primary: Number of Participants With Adverse Events — 3; 3; 5; 3 Participants

Primary: Change in 24-hour Mean Weighted Glucose (MWG) From Baseline to End of Treatment (Week 4) Using the Continuous Glucose Monitoring (CGM) System — -18.2; 5.8 mg/dL — p=<0.001

Primary: Average Leg Pain at 1 Month Measured Using the Numeric Pain Scale — 3.3; 3.7 units on a scale

Primary: Change From Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -14.37; -14.40; -13.18 units on a scale — p=0.630

Primary: Cognitive Function Measured by MCCB Composite Score — 35.39; 30.73 units on a scale

Primary: Mean Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to the End of 8 Weeks of Therapy. — 32.4; 30.4; 21.7; 19.0 units on a scale

Primary: Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD) — 24; 57 percentage of participants — p=.036

Primary: Time to Recurrent Biliary Obstruction — 711; 357 days — p=0.530